1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

LegoChem Brings Late Christmas Cheer With $1.7bn ADC Deal

Janssen Gets Worldwide Rights To Trop2-Directed ADC

 
• By Jung Won Shin

LegoChem Biosciences has sealed yet another sizable out-licensing agreement with a global big pharma firm, this time with Janssen, underlining the continued keen global interest in ADCs.

christmas gift
LegoChem/Janssen ADC Deal Biggest So Far For Korean Firm • Source: Shutterstock

More signs of improvement in South Korean biopharma alliances emerged right at the end of 2023, with LegoChem Biosciences, Inc. announcing an up to $1.7bn antibody-drug conjugate (ADC) deal with Janssen Biotech Inc. just after Christmas. 

Key Takeaways

  • Deal marks another major deal with a global big pharma for LegoChem and the biggest out-licensing so far by a Korean biopharma firm.

The much anticipated out-licensing agreement for worldwide development and commercialization rights to the Korean biotech’s Trop2-directed oncology ADC LCB84 (Trop2-MMAE)...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from South Korea

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

More from Focus On Asia

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis